Hikma Pharmaceuticals PLC - EIP Vesting
LONDON, 7 March 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 25 February 2022 under the 2014 Executive Incentive Plan ("EIP") Element B and 25 February 2021 under the EIP Element C.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Bassam Kanaan
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Bassam Kanaan | |
| 2 | Reason for the notification | ||
| a) | Position/status | PDMR | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element B and EIP Element C. All Shares were retained. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | EIP Award, Element B: 20,588 | ||
| Nil | EIP Award, Element C: 13,378 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 33,966 | |
| e) | Date of the transaction | 6 March 2024 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
Julie Hill
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Julie Hill | |
| 2 | Reason for the notification | ||
| a) | Position/status | PDMR | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element B. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 5,339 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 5,339
| |
| e) | Date of the transaction | 6 March 2024 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
| b) | Nature of the transaction | Shares sold to cover tax following the vesting of conditional awards under the EIP Element B. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £19.275 | 2,190 | ||
| d) | Aggregated information | Price(s): £19.275 Volume(s): 2,190 Total(s): £42,211.36
| |
| e) | Date of the transaction | 6 March 2024 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
Helen Middlemist
Group Company Secretary
+44 (0)20 7399 2760
7 March 2024
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.